Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (August 2017)
23 slides from Pyc Therapeutics's investor presentation, Sep 1, 2017
Slide 1: Phylogica (ASX:PYC) Presentation
For personal use only Phylogica (ASX:PYC) Presentation By CEO Stephanie Unwin and CSO Dr Robert Hayes August 2017
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: About Us
About Us For personal use only Who are What do Why we? we do? Peptides? Perth-based biotech Improve existing drug Peptides are naturally focused on creating a delivery and identify occurring protein blocks in commercial platform carriers and cargoes the body with the to deliver drugs into from our p
Slide 4: Key Investment Highlights
Key Investment Highlights For personal use only • Addressing a large unmet market need - $250Bn for biologics targeting “undruggable” targets and $110Bn cancer treatment • Derisked investment opportunity - progressing 3 asset groups - intracellular delivery, biologic therapeutic solutions and new dr
Slide 5: Financial details
Financial details For personal use only Phylogica (ASX:PYC) share price August Current share price: $0.045 2016 -2017 0.06 0.05 Shares on issue: 2.12Bn 0.04 0.03 Market Cap: $95.4M 0.02 0.01 0 Cash : $9.5M
Slide 6: Experienced Management Team
Experienced Management Team For personal use only In mid 2017 Phylogica revitalised its management team with senior Pharma and commercial executives : Core Management Team Ms Unwin was previously an executive general manager at Dr Hayes was previously the Head of Biologics at Synergy. She has held s
Slide 7: Three focus areas to validate the commercial platform
Three focus areas to validate the commercial platform For personal use only 1 Improve FPP’s endosomal escape activity • New FPPs to be identified by assays • Protein engineering work Outcome: o Fine tuning existing FPPs active window and strategic substitution • 13 new FPP families announced last qu
Slide 8: Disruptive Drug Delivery Platform
For personal use only Disruptive Drug Delivery Platform Overcoming existing drug delivery challenges with FPPs
Slide 9: Platform Technology: The Phylomer Library
Platform Technology: The Phylomer Library For personal use only PYC’s Phylomer Library is made up of 35 biodiverse genetic material derived from volcanoes, geysers and undersea vents. The library enables the discovery of new phylomers with potential for: • Drug delivery agents: Functional Penetratin
Slide 10: Conventional Drug Delivery Challenges
Conventional Drug Delivery Challenges For personal use only The Our problem? solution? CELL MEMBRANE CPP drugs Conventional drugs are Development of cell- delivered via Cell penetrating peptides Penetrating Peptides to effectively (CPPs) which are mostly endosomes penetrate cell walls trapped within
Slide 11: About Phylogica's proprietary cell penetrating peptides – FPPs
About Phylogica’s proprietary cell penetrating peptides – FPPs (Functional Penetrating Phylomers) can deliver a diverse For personal use only Phylogica’s FPPs range of “biologic cargoes” into cells overcome existing challenges to drug delivery. Phylogica’s FPP FPPs attach to “biologic cargoes” (ie.
Slide 12: FPPs are able to deliver a diverse range and size of cargos
FPPs are able to deliver a diverse range and size of cargos Conceptual stage Validated efficacious delivery For personal use only Example cargos and targeted diseases that can be delivered with FPPs Cargo class Example cargo Example disease Progress1 Cargo size RNA PMO Duchenne muscular dystrophy Mu
Slide 13: Best-in-class: Phylogica's FPP
Best-in-class: For personal use only 159-fold Phylogica’s FPP 37-fold 50 As conventional Cell Penetrating Peptides 40 (CPPs) are mostly trapped inside the cells, Drug Deliver Efficiency Phylogica’s FPPs: 30 (% +ve Cells) • enables effective delivery of its biological cargoes as it enables the drug t
Slide 14: Best-in-Class: Phylogica's FPP
Best-in-Class: Phylogica’s FPP For personal use only Constant improvement for potency and cell-specificity FPP Enhancement 26 August 2017 Relative FPP Uptake 26 August 2017 Proteins: Unreacted Dye Reacted/unreacted Dye 100 4uM 55 Alternative Reacted Dye scaffolds Enzymes Percentage 450nm +ve cells (
Slide 15: Commercial Opportunities: FPP
Commercial Opportunities: FPP For personal use only • Addressing the massive $250Bn (CAGR 10.6%) market of drug delivery • Improving delivery of existing/new drugs • FPPs form the basis of Phylomer Therapeutics with the potential to be a fully integrated drug delivery platform: o Compatible with wid
Slide 16: Biologic Cargoes: Targeting disease with Phylomer Peptides
For personal use only Biologic Cargoes Targeting disease with Phylomer Peptides
Slide 17: Our Lead Biological Cargo: iMyc
Our Lead Biological Cargo: iMyc For personal use only How is What is What is iMyc Myc? iMyc? effective? Cell Growth • PYC’s iMyc (Myc inhibitor) • Current Gold Standard reduces over-expressed OmoMyc protein Myc Metabolism Myc in cells, effectively • OmoMyc has low potency Apoptosis killing off the c
Slide 18: PYC's leading cancer therapeutic program: FPP-iMyc
PYC’s leading cancer therapeutic For personal use only program: FPP-iMyc • 7 out of 10 cancers involve and overactive Myc protein • Phylogica’s lead program FPP-iMyc is best-in-class • iMyc comparable or better than the ‘Omomyc’ gold standard in killing Myc-addicted cells • Target market – $110 Bn N
Slide 19: Robust Product Pipeline
Robust Product Pipeline For personal use only • Phylomer screens against validated and clinically relevant oncology targets • cMyc, N-Myc, Stat5 and YB1 • Validated hits already exceed potency of gold standard inhibitors • Stat5 and YB 1 collaborations with Dana Farber Institute, Harvard Medical Sch
Slide 20: Partnering Strategy
Partnering Strategy For personal use only Phylogica has a variety of academic and industry partnerships set up with key players in the industry working together to mine the Phylomer Library for new drug targets and to progress FPP’s with various ‘biological cargoes’.
Slide 21: Current activities
Current activities For personal use only The principle: sensitive resistant • Our collaboration aims at the isolation of Phylomers that can help killing multi-drug resistant “super bugs” Antibiotic ✔ ✗ Phylomer ✗ ✗ • Phylomers are expected to increase the potential to kill bacteria Phylomer/Antibiot
Slide 22: Commercial Strategy
2016 Commercial • Validation of FPP delivery technology For personal use only • Proof of concept triple delivery negative Strategy breast cancer cell line • Improved delivery of biologic cargoes into cells in vitro and in vivo • FPP-Omomyc shown to reduce lympthoma cells in spleen and bone marrow 20
Slide 23: Thank you
For personal use only Thank you For more information contact Stephanie Unwin at stephanieu@phylogica.com